OWC Pharma (OWCP) Advances Study & Expands into Consulting
Ryan Allway
May 3rd, 2016
News, Top News
The medical cannabis industry has been a hot topic within the investment community over the past month after GW Pharmaceuticals plc (NASDAQ: GWPH) reported positive results in the first of two clinical trials evaluating Epidiolex for the treatment of rare forms of epilepsy. In 120 randomized patients suffering from Dravet syndrome, Epidiolex reduced the number of monthly seizures by 39% compared to 11% for patients receiving placebo.
The news sent shares in a number of marijuana companies sharply higher including Medical Marijuana Inc. (OTC: MJNA) and others. In reality, few companies are conducting high quality clinical trials evaluating the safety and efficacy of cannabinoids across indications. Popular marijuana stocks may command the headlines, but lesser known names may provide the greatest potential upside from eventual FDA approvals.
OWC Pharmaceutical Corp. (OTC: OWCP) is an Israeli based developer of cannabinoid-based therapies targeting a variety of different indications. In partnership with leading Israeli hospitals and scientific institutions, the company is working with internationally renowned investigators to conduct clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, with an initial focus on multiple myeloma.
The company recently announced the completion of in-vitro testing of its formulation for the treatment of multiple myeloma cell lines. After observing dose-dependent efficacy, the team is gearing up for pre-clinical studies on mice designed to assess the safety and efficacy of these compounds before eventually moving on to human subjects. Multiple myeloma accounts for 2% of all cancer deaths and is one of the most deadly forms of the disease.
“The preliminary results of the in-vitro studies of our cannabinoid formulation on multiple myeloma were very positive, so we have decided to advance the study on live animals, in this case mice,” said Dr. Yehuda Baruch, OWC’s Director of Research in a recent press release discussing the early-stage in-vitro results. “We hope that the efficacy and safety trial will give us the comfort we need to continue on to the human stage of testing.”
CFN Media recently interviewed the OWC Pharmaceuticals management team to discuss the company’s latest progress and where it’s headed.
OWC Pharmaceuticals’ early-stage in-vitro results were very promising. Specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. Over the long-term, the company plans to expand these trials to target other indications like psoriasis, fibromyalgia, migraines, and post-traumatic stress disorder (PTSD).
In addition to its clinical trials, the company also provides consulting services to companies and governments navigating the complex international cannabis regulatory framework. The team recently launched its services in the United States, where they help companies seeking to start medical marijuana businesses. Their services include regulatory compliance services and patient-care consultancy services to both U.S. and E.U. clients.
These consulting services are similar to those offered by other companies, like American Cannabis Company Inc. (OTC: AMMJ), but focus on the medical side of the business rather than the recreational. In particular, the company’s patient-focused consulting services are relatively unique within cannabis industry. These areas of focus leverage its expertise in running the research division.
OWC Pharmaceuticals has an experienced management team and advisory board at the helm to execute on its research and consulting divisions. President and CEO Mordechai Bignitz and Ziv Turner both have extensive experience in founding and investing in companies. On the science side, Dr. Yehuda Baruch headed the Israeli Ministry of Health’s Medical Marijuana Program between 2003 and 2013, while CSO Dr. Asaf Toker was Medical Director of a major health company.
Investors interested in capitalizing on the medical cannabis industry following GW Pharmaceuticals’ favorable clinical results may want to check out OWC Pharma as an attractive and lesser-known play in the burgeoning industry.
For more information, visit the company’s website at http://www.owcpharma.com/.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Resolve Digital Health Inc. committed to establishing a standard of care missing from the medical cannabis industry until now.
Flora is building a connected, design-led collective, of plant-based wellness and lifestyle brands, that delivers the most compelling customer experiences in the world, one community at a time.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
